Emtricitavine

2 Drugs classified under this active ingredient

Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Emtricitavine 200 mg, Rilpivirine (as HCl) 25 mg, Tenofovir Disoproxil (as Fumarate) 245 mg.
F.C. TABS: 30. Adults: 1 tab dly with
meal. Under 18 yrs: Not recommend.
Over 65 yrs: use with caution. Not
recommend. in pts. with CLcr < 50 ml/
min. See lit.
Comb. of emtricitabine, tenofovir
disoproxil fumarate and rilpivirine for use
as a complete regimen for the tmt of HIV-1
infect. in adult pts with no antiretrov. tmt
hist. and with HIV-1 RNA less than or equal
to 100,000 copies/mL at the start of ther.,
and in certain virologic. suppress. (HIV-1
RNA <50 copies/mL) adult pts on a stable
antiretrov. regimen at start of ther. in order
to replace their curr. antiretrov. tmt
regimen.
C/I: Hypersens. to act. subst. or to any
excip., co-admin. with CYP3A induc. and
gastric pH incr.: anticonvuls. –
carbamazepine, oxcarbazapine,
phenobarbital, phenytoin;
antimycobacter. – rifampin, rifapentine;
PPI – dexlansoprazole, esomeprazole,
lansoprazole, omeprazole, antoprazole,
rabeprazole; glucocorticoid systemic
dexamethasone (more than a single
dose); St. John’s wort (Hypericum
perforatum).

Nucleoside Reverse Transcriptase Inhibitor. Emtricitavine 200 mg, Tenofovir Disoproxil 245 mg.
F.C. TABS: 30. 1 tab dly with
food. Child: Under 18 yrs. not
recommend.
In comb. with other antiretrovirals to
treat HIV-1 infects.
C/I: Severe ren. impair., lact.